Drug Profile
APL 1501
Alternative Names: APL-1301; APL-1501Latest Information Update: 25 Apr 2024
Price :
$50
*
At a glance
- Originator Asieris Pharmaceuticals
- Class Antibacterials; Antineoplastics
- Mechanism of Action Methionine aminopeptidase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Urinary tract infections
- Preclinical Solid tumours
- No development reported Bladder cancer; Urogenital cancer
Most Recent Events
- 17 Apr 2024 Asieris Pharmaceuticals announces intention to conduct regulatory discussions with the US FDA regarding the registration clinical development plan in 2024
- 17 Apr 2024 Asieris Pharmaceuticals plans clinical trials for Bladder cancer (Combination therapy, Second-line therapy or greater) in USA in 2024
- 28 Nov 2023 No recent reports of development identified for phase-I development in Bladder-cancer(Combination therapy, In volunteers) in Australia (PO, Tablet)